Guide Regarding Choice of Second-line Therapy to Obtain a High Cumulative Cure Rate

Helicobacter

Volumn 17, Issue 4, 2012, Pages 243-245

  Graham, David Y ^a   Calvet, Xavier ^b,c  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b HOSPITAL DE SABADELL   (Spain)

^c PARC TAULÍ HOSPITAL UNIVERSITARI   (Spain)

Author keywords

Bismuth; Fluoroquinolones; Helicobacter pylori infection; Second line therapy; Tetracycline; Therapy; Treatment success

Indexed keywords

AMOXICILLIN; BISMUTH; CLARITHROMYCIN; LEVOFLOXACIN; METRONIDAZOLE; PROTON PUMP INHIBITOR; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TETRACYCLINE; TINIDAZOLE;

ANTIBIOTIC SENSITIVITY; CLINICAL EFFECTIVENESS; DRUG CHOICE; DRUG COST; DRUG SAFETY; DRUG TREATMENT FAILURE; EDITORIAL; ERADICATION THERAPY; HELICOBACTER INFECTION; HUMAN; PRIORITY JOURNAL; TREATMENT OUTCOME; TREATMENT PLANNING;

ANTI-BACTERIAL AGENTS; FEMALE; HELICOBACTER INFECTIONS; HUMANS; MALE; OFLOXACIN;

HELICOBACTER PYLORI;

EID: 84863604336     PISSN: 10834389     EISSN: 15235378     Source Type: Journal    
DOI: 10.1111/j.1523-5378.2012.00952.x     Document Type: Editorial

References (10)

1. Manfredi M, Bazzarri B, de'Angelis GL. Helicobacter pylori infection: sequential therapy followed by levofloxacin-containing triple therapy provides a good cumulative eradication rate. Helicobacter 2012; DOI: (In press).
2. Lee YC, Wu HM, Chen TH, et al. A community-based study of Helicobacter pylori therapy using the strategy of test, treat, retest, and re-treat initial treatment failures. Helicobacter 2006;11:418-24.
3. Rokkas T, Sechopoulos P, Robotis I, Margantinis G, Pistiolas D. Cumulative H. pylori eradication rates in clinical practice by adopting first and second-line regimens proposed by the Maastricht III consensus and a third-line empirical regimen. Am J Gastroenterol 2009;104:21-5.
4. Malfertheiner P, Megraud F, O'Morain C, Hungin AP, Jones R, Axon A, Graham DY, Tytgat G. Current concepts in the management of Helicobacter pylori infection-- the Maastricht 2-2000 Consensus Report. Aliment Pharmacol Ther 2002;16:167-80.
5. Graham DY, Rimbara E. Helicobacter pylori therapy in the west. Japanese J Helicobacter Res 2012;13:4-9.
6. Li Y, Huang X, Yao L, Shi R, Zhang G. Advantages of moxifloxacin and levofloxacin-based triple therapy for second-line treatments of persistent Helicobacter pylori infection: a meta analysis. Wien Klin Wochenschr 2010;122:413-22.
7. Saad RJ, Schoenfeld P, Kim HM, Chey WD. Levofloxacin-based triple therapy versus bismuth-based quadruple therapy for persistent Helicobacter pylori infection: a meta-analysis. Am J Gastroenterol 2006;101:488-96.
8. Miehlke S, Krasz S, Schneider-Brachert W, et al. Randomized trial on 14 versus 7 days of esomeprazole, moxifloxacin, and amoxicillin for second-line or rescue treatment of Helicobacter pylori infection. Helicobacter 2011;16:420-6.
9. Rimbara E, Fischbach LA, Graham DY. Optimal therapy for Helicobacter pylori infections. Nat Rev Gastroenterol Hepatol 2011;8:79-88.
10. Fischbach LA, van ZS, Dickason J. Meta-analysis: the efficacy, adverse events, and adherence related to first-line anti-Helicobacter pylori quadruple therapies. Aliment Pharmacol Ther 2004;20:1071-82.